Safety of apatinib plus S‑1 for advanced solid tumor as palliative treatment

Chen,Siying; Sun,Jifeng; Zhao,Lujun; Sun,Yunguang; Jia,Dan; Song,Yongchun; Luo,Jing; Lei,Hailong; Liu,Ningbo

doi:10.3892/etm.2020.9494

Safety of apatinib plus S‑1 for advanced solid tumor as palliative treatment

Authors:
- Siying Chen
- Jifeng Sun
- Lujun Zhao
- Yunguang Sun
- Dan Jia
- Yongchun Song
- Jing Luo
- Hailong Lei
- Ningbo Liu
View Affiliations

Affiliations: Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer/Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Pathology, Medical College of Wisconsin Cancer Center, Milwaukee, WI 53226, USA, Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, Jilin 130000, P.R. China, Department of Radiation Oncology, The People's Hospital of Wuhai Inner Mongolia, Wuhai, Inner Mongolia 016000, P.R. China
Published online on: November 19, 2020 https://doi.org/10.3892/etm.2020.9494
Article Number: 62
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the safety of apatinib plus S‑1 in treating advanced solid tumors after failure of two or more lines of chemotherapy. A total of 33 patients with advanced cancer treated between April 2016 to March 2019 were retrospectively analyzed. Of these, 13 patients had non‑small cell lung cancer (NSCLC), 13 patients had SCLC, 4 patients had esophageal cancer and 3 had cervical cancer. All patients were treated with apatinib 250 mg once daily combined with S‑1 60 mg/m² twice daily for 14 days, repeated every 3 weeks. Adverse reactions were observed until aggravation of adverse reactions beyond the tolerable range or disease progression, and the survival rate and clinical benefits were calculated. The results suggested that the incidence rate of adverse effects (grade 3‑4) was 45.5% (15/33). The top three severe adverse effects were hypertension (15.2%), thrombocytopenia (12.1%) and proteinuria (9.1%). A total of 2 patients with lung squamous‑cell carcinomas died of severe pulmonary hemorrhage. Other adverse reactions were tolerated in the cohort. A total of 10 patients achieved partial response and the objective response rate was 30.3%. Furthermore, 13 patients achieved stable disease and 10 patients had progressive disease, and accordingly, the disease control rate was 72.7%. In conclusion, apatinib plus S‑1 for advanced solid tumor patients as palliative treatment have a certain efficacy and was relatively safe but should be used with caution in patients with squamous‑cell lung carcinoma and the efficacy and safety requires further assessment.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
2	van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012.PubMed/NCBI View Article : Google Scholar
3	Song Z, Yu X, Lou G, Shi X and Zhang Y: Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther. 10:1821–1825. 2017.PubMed/NCBI View Article : Google Scholar
4	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000.PubMed/NCBI View Article : Google Scholar
5	Roudsari LC and West JL: Studying the influence of angiogenesis in in vitro cancer model systems. Adv Drug Deliv Rev. 97:250–259. 2016.PubMed/NCBI View Article : Google Scholar
6	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.PubMed/NCBI View Article : Google Scholar
7	Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X and Kerbel RS: A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma11ontario graduate scholarship in science and technology (J.M.L. Ebos); sunnybrook trust for medical research (G. Bocci); and NIH grant CA41223, Canadian institutes for health research, and national cancer institute of Canada (R.S. Kerbel). Mol Cancer Res. 2:315–326. 2004.
8	Geng R, Song L, Li J and Zhao L: The safety of apatinib for the treatment of gastric cancer. Expert Opin Drug Saf. 17:1145–1150. 2018.PubMed/NCBI View Article : Google Scholar
9	Brower V: Apatinib in treatment of refractory gastric cancer. Lancet Oncol. 17(e137)2016.PubMed/NCBI View Article : Google Scholar
10	Ding L, Li QJ, You KY, Jiang ZM and Yao HR: The use of apatinib in treating nonsmall-cell lung cancer: Case report and review of literature. Medicine (Baltimore). 95(e3598)2016.PubMed/NCBI View Article : Google Scholar
11	Li F, Liao Z, Zhao J, Zhao G, Li X, Du X, Yang Y and Yang J: Efficacy and safety of Apatinib in stage IV sarcomas: Experience of a major sarcoma center in China. Oncotarget. 8:64471–64480. 2017.PubMed/NCBI View Article : Google Scholar
12	Scott A, Messersmith W and Jimeno A: Apatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 51:223–229. 2015.PubMed/NCBI View Article : Google Scholar
13	Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 34:1448–1454. 2016.PubMed/NCBI View Article : Google Scholar
14	Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al: Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 135:1961–1969. 2014.PubMed/NCBI View Article : Google Scholar
15	Li J and Wang L: Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma. Onco Targets Ther. 10:3965–3969. 2017.PubMed/NCBI View Article : Google Scholar
16	Li F, Zhu T, Cao B, Wang J and Liang L: Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur J Cancer. 84:184–192. 2017.PubMed/NCBI View Article : Google Scholar
17	Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z, et al: Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 14(820)2014.PubMed/NCBI View Article : Google Scholar
18	Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, et al: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 56:2602–2606. 1996.PubMed/NCBI
19	Yumine K and Kawahara M: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Gan To Kagaku Ryoho. 33 (Suppl 1):189–192. 2006.PubMed/NCBI(In Japanese).
20	Zhang H, Xiong J, Guo L, Patel N and Guang X: Integrated traditional Chinese and western medicine modulator for overcoming the multidrug resistance with carbon nanotubes. RSC Adv. 5:71287–71296. 2015.
21	Wu P, Li S and Zhang H: Design real-time reversal of tumor multidrug resistance cleverly with shortened carbon nanotubes. Drug Des Devel Ther. 8:2431–2438. 2014.PubMed/NCBI View Article : Google Scholar
22	Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, et al: Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 70:7981–7991. 2010.PubMed/NCBI View Article : Google Scholar
23	Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al: Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 17:286–301. 2017.PubMed/NCBI View Article : Google Scholar
24	Wang SY, Liu Z, Ou W, Li N, Wu HQ, Mao XY and Yuan C: Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. J Clin Oncol. 35 (15 Suppl)(e20626)2017.
25	Yan X, Wang Q, Wang H, Li P, Zhang G, Zhang M, Zheng X, Yang J, Zhang X and Ma Z: Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: Results from a single-center retrospective study. J Cancer Res Clin Oncol. 145:235–240. 2019.PubMed/NCBI View Article : Google Scholar
26	Roskoski R Jr: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 62:179–213. 2007.PubMed/NCBI View Article : Google Scholar
27	Kamba T and McDonald D: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 96:1788–1795. 2007.PubMed/NCBI View Article : Google Scholar
28	Scott LJ: Apatinib: A review in advanced gastric cancer and other advanced cancer. Drugs. 78:747–758. 2018.PubMed/NCBI View Article : Google Scholar
29	Kilickap S, Abali Hs and Celik I: Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol. 21:3542–3543. 2003.PubMed/NCBI View Article : Google Scholar
30	Clark JW, Eder JP, Ryan D, Lathia C and Lenz HJ: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 11:5472–5480. 2005.PubMed/NCBI View Article : Google Scholar
31	Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B, et al: Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 12:426–437. 2007.PubMed/NCBI View Article : Google Scholar
32	Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 9:215–221. 2008.PubMed/NCBI View Article : Google Scholar
33	Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, Morimoto K, Kimura M, Aoyama H, Ota J, et al: A phase II study of S-1 in patients with metastatic breast cancer-a Japanese trial by the S-1 cooperative study group, breast cancer working group. Breast Cancer. 11:194–202. 2004.PubMed/NCBI View Article : Google Scholar
34	Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y and Shirao K: Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol. 17:968–973. 2006.PubMed/NCBI View Article : Google Scholar
35	Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S and Saito H: A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 61:615–621. 2008.PubMed/NCBI View Article : Google Scholar
36	Takakuwa O, Oguri T, Maeno K, Ozasa H, Iwashima Y, Miyazaki M, Kunii H, Takano Y, Mori T, Sato S and Ueda R: Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens. Oncol Lett. 1:147–150. 2010.PubMed/NCBI View Article : Google Scholar
37	Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996.PubMed/NCBI View Article : Google Scholar
38	Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res. 78:748–755. 1987.PubMed/NCBI
39	Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S and Ueda R: The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer. 49:345–351. 2005.PubMed/NCBI View Article : Google Scholar
40	Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53:4004–4009. 1993.PubMed/NCBI
41	Kaira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Iwasaki Y, Shimizu K, Iijima H, Tsurumaki H, Tomizawa Y, et al: Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 68:253–257. 2010.PubMed/NCBI View Article : Google Scholar
42	Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L, et al: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med. 8:841–849. 2002.PubMed/NCBI View Article : Google Scholar
43	Hood JD, Meininger CJ, Ziche M and Granger HJ: VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 274:H1054–H1058. 1998.PubMed/NCBI View Article : Google Scholar
44	Alexandrescu D, Vaillant J and Dasanu C: Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors. Clin Exp Dermatol. 32:71–74. 2007.PubMed/NCBI View Article : Google Scholar
45	Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III, Gaudreault J, Damico LA, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 22:2184–2191. 2004.PubMed/NCBI View Article : Google Scholar
46	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006.PubMed/NCBI View Article : Google Scholar
47	Socinski MA, Novello S, Sanchez JM, Brahmer JA, Govindan R, Belani CP, Atkins JN, Gillenwater HH, Palleres C and Chao RC: Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. J Clin Oncol. 24 (18 Suppl)(S7001)2006.